A study conducted at the University of Michigan showed that Zanubrutinib, an oral drug, has been seen to shrink lymphoma cancer, one of the most common cancers, in 80% of the patients. 20 patients with slow-growing cancer, called marginal zone lymphoma, saw an 80% of reduction in the cancer cells after the intake of the drug Zanubrutinib. After this research, Zanubrutinib has been approved by the Food and Drug Administration to be used on a contingent basis for adults suffering from marginal zone lymphoma. However, researchers are looking for more effective and tolerable treatments.
Read More from SciTechDaily
